Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial

Moderate doses of glucocorticoids result in improvements in nearly all patients with polymyalgia rheumatica, but related adverse events are common in older individuals. We aimed to evaluate whether treatment with baricitinib (a Janus kinase 1/2 inhibitor) results in disease control without the use o...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Lancet. Rheumatology 2025-01
Hauptverfasser:	Saraux, Alain, Carvajal Alegria, Guillermo, Dernis, Emmanuelle, Roux, Christian, Richez, Christophe, Tison, Alice, Quere, Baptiste, Jousse-Joulin, Sandrine, Guellec, Dewi, Marhadour, Thierry, Kervarrec, Patrice, Cornec, Divi, Le Henaff, Catherine, Lesven, Sandra, Nowak, Emmanuel, Souki, Aghiles, Devauchelle-Pensec, Valérie
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!